Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes

Rhea-AI Filing Summary

Kiora Pharmaceuticals President and CEO Brian M. Strem reported a tax-related stock transaction. On March 3, 2026, he disposed of 238 shares of common stock at $2.02 per share as a tax-withholding disposition, a method of paying tax obligations using shares. After this transaction, he directly owned 45,865 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Strem Brian M.

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CA 92024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		F		238	D	$2.02	45,865	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Net Share settlement, shares withheld for employee tax obligation upon vesting of restricted stock.

	/s/ Melissa Tosca, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did KPRX CEO Brian Strem report on this Form 4?

Brian M. Strem reported a tax-withholding disposition of 238 Kiora Pharmaceuticals common shares on March 3, 2026, at $2.02 per share. After the transaction, he directly owned 45,865 common shares of Kiora Pharmaceuticals Inc.

Was the KPRX CEO’s Form 4 transaction an open-market stock sale?

No. The Form 4 describes the transaction as a tax-withholding disposition, coded “F,” meaning shares were disposed of to satisfy tax obligations, not sold in an open-market trade. This is a common administrative method for handling equity-related tax liabilities.

How many Kiora Pharmaceuticals (KPRX) shares did the CEO dispose of?

The CEO disposed of 238 common shares of Kiora Pharmaceuticals Inc. at a reported price of $2.02 per share. The transaction is identified as a tax-withholding disposition, used to cover tax liabilities associated with equity compensation.

How many KPRX shares does CEO Brian Strem hold after this Form 4 transaction?

Following the reported tax-withholding disposition, Brian M. Strem directly owns 45,865 shares of Kiora Pharmaceuticals common stock. This updated holding reflects his position after disposing of 238 shares on March 3, 2026, to satisfy related tax obligations.

What does transaction code “F” mean in the KPRX CEO’s Form 4?

Transaction code “F” represents a payment of exercise price or tax liability by delivering securities. In this Form 4, it shows that Brian M. Strem used 238 common shares of Kiora Pharmaceuticals to cover tax obligations, rather than executing a normal market sale.

Is the KPRX CEO’s Form 4 transaction classified as a buy or a sell?

The transaction is classified as a disposition, specifically a tax-withholding disposition rather than a standard sale. It reduced the CEO’s share count by 238 shares, which were used to satisfy tax obligations related to equity awards or similar compensation.